Alexza (NASDAQ:ALXA) MDC is a specialty pharmaceutical company developing products with faster onset of therapeutic effect. The company’s core technology platform, Staccato™, enables rapid administration of most small molecule drugs to treat acute and intermittent conditions. The Staccato platform can deliver drugs to the body and brain within seconds, thus accelerating drug action. The Staccato technology also enables patients to titrate their medication to the lowest effective dose. By improving therapy for acute and intermittent conditions, Alexza will capitalize on large and growing therapeutic categories. As a specialty pharmaceutical company, Alexza will develop its own product pipeline, focusing initially on central nervous system (CNS) indications representing more than $20 billion in annual U.S. sales. The company may also partner its technology with pharmaceutical companies on proprietary compounds.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 01/05/05 | Series D | 52M | Third Wave Ventures, Clarus Ventures, AIG Capital, New Leaf Venture Partners, Versant Ventures, Advanced Technology Ventures, InterWest Partners, Advanced Technology Ventures, Grotech Capital, Research Technology Ventures, RTI International, Carbon Trust Investment Partners, Rising Stars Growth Fund, NorthStar Equity Investors, Porton Capital, Synergis Technologies | Unknown |
| 05/21/13 | Debt | 25M | Unknown |
People
Michael Simms (SVP Operations & Manufacturing)
Elaine Stracker (VP Intellectual Property)
Ernest Mario (President/CEO)
August Moretti (CFO/General Counsel)
Isaac Stein (Board Member)
View more details about all 22 people at Alexza Pharmaceuticals